TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19422410

Group type: EXPERIMENTAL
Intervention: High light intensity (600 lux)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Medium light intensity (200 lux)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Low light intensity (50 lux)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 17340897

Group type: EXPERIMENTAL
Intervention: Early Loaded (EL) implants
Number of subjects: 17

Group type: COMPARATOR
Intervention: Delayed Loaded (DL) implants
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both EL and DL implants
Number of subjects: 17
Study: 15003147

Group type: EXPERIMENTAL
Intervention: 2 mg/d of haloperidol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 8 mg/d of haloperidol
Number of subjects: 40
Study: 11107921

Group type: EXPERIMENTAL
Intervention: Unilateral salpingo‐oophorectomy coupled with comprehensive surgical staging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Abdominal hysterectomy and bilateral salpingo‐oophorectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DNA ploidy
Number of subjects: 0
Study: 9263114

Group type: EXPERIMENTAL
Intervention: Prophylactic granulocyte transfusions (GTX) with adequate doses of compatible leukocytes
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8
Study: 8472980

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 800 mg twice daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ranitidine 300 mg twice daily
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ranitidine or ranitidine bismuth citrate
Number of subjects: 24
Study: 3814227

Group type: EXPERIMENTAL
Intervention: 8 g L-aspartic acid for 7 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: 50 mg chlorpromazine + 60 mg diazepam daily
Number of subjects: 31
Study: 31531601

Group type: EXPERIMENTAL
Intervention: TVS RT‐3D‐HyCoSy
Number of subjects: 83
Study: 28181973

Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham Reiki
Number of subjects: 46

Group type: COMPARATOR
Intervention: Standard of Care
Number of subjects: 46
Study: 26275472

Group type: EXPERIMENTAL
Intervention: Free glasses, education on their use, and a teacher incentive
Number of subjects: 728

Group type: COMPARATOR
Intervention: Glasses prescriptions only
Number of subjects: 728
Study: 23019151

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 468
Study: 22852118

Group type: EXPERIMENTAL
Intervention: Cephazolin, 1.0 g i.v., once postoperatively
Number of subjects: 160

Group type: COMPARATOR
Intervention: Amoxicillin‐clavulanate, 1000 mg orally for 7 days postoperatively
Number of subjects: 160
Study: 19161365

Group type: EXPERIMENTAL
Intervention: Moderate-intensity aerobic exercise (walking for 40 min at 50-60% VO(2peak))
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (sitting quietly for 40 min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both exercise and control
Number of subjects: 24
Study: 16948661

Group type: EXPERIMENTAL
Intervention: Buccal infiltration of 1.8 mL
Number of subjects: 31

Group type: COMPARATOR
Intervention: Buccal infiltration of 0.9 mL plus lingual infiltration of 0.9 mL
Number of subjects: 31
Study: 12597221

Group type: EXPERIMENTAL
Intervention: Progressive resistive training program for torso rotation
Number of subjects: 20
Study: 9884382

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (r-hirudin) regimen A1 (0.4 mg/kg bolus and then 0.15 mg/kg/h)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (r-hirudin) regimen A2 (0.2 mg/kg bolus and then 0.1 mg/kg/h)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Recombinant hirudin (r-hirudin)
Number of subjects: 82
Study: 8905422

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) at 1 mg/kg per hour over 24 h
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 24
Study: 1892185

Group type: EXPERIMENTAL
Intervention: SLOW MAG (535 mg every 4 hours)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: oral ritodrine (20 mg every 4 hours)
Number of subjects: 75

Group type: COMPARATOR
Intervention: no therapy (control)
Number of subjects: 75
Study: 6357256

Group type: EXPERIMENTAL
Intervention: Routine chest physiotherapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: No physiotherapy (Control)
Number of subjects: 102
Study: 30276833

Group type: EXPERIMENTAL
Intervention: 60 μg of beraprost (three tablets)
Number of subjects: 29
Study: 28933605

Group type: EXPERIMENTAL
Intervention: Early isometric loading of the rotator cuff
Number of subjects: 30

Group type: COMPARATOR
Intervention: Primary passive motion
Number of subjects: 30
Study: 26669795

Group type: EXPERIMENTAL
Intervention: Online education
Number of subjects: 590

Group type: COMPARATOR
Intervention: In-person group education
Number of subjects: 590
Study: 25182454

Group type: EXPERIMENTAL
Intervention: Dalteparin subcutaneously twice daily, initial weight-based dosing: infants (< 12 months) 150 IU kg(‐1), children (1‐12 years) 125 IU kg(‐1), adolescents (13‐18 years) 100 IU kg(‐1)
Number of subjects: 18
Study: 23211656

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including counselling on GWG, physical activity, and healthy eating at five routine visits
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 399

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 399
Study: 20705432

Group type: EXPERIMENTAL
Intervention: arthrocentesis followed by intra‐articular injection of sodium hyaluronate (SH)
Number of subjects: 25

Group type: COMPARATOR
Intervention: arthrocentesis
Number of subjects: 25
Study: 16936327

Group type: EXPERIMENTAL
Intervention: Etoricoxib 30 mg qd
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg qd
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study: 17012878

Group type: EXPERIMENTAL
Intervention: Menactra (MCV-4) vaccine
Number of subjects: 220

Group type: COMPARATOR
Intervention: Menomune (PSV-4) vaccine
Number of subjects: 220
Study: 15259387

Group type: EXPERIMENTAL
Intervention: HIV-positive group
Number of subjects: 33

Group type: COMPARATOR
Intervention: HIV-negative group
Number of subjects: 33
Study: 10421303

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches prescribed by GPs for up to 12 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GP counselling with nicotine-patch treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: GP counselling alone
Number of subjects: 30
Study: 7605024

Group type: EXPERIMENTAL
Intervention: Sevoflurane (3% during transition to 1.24 MAC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Desflurane (9% during transition to 1.24 MAC)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sevoflurane (0.41, 0.83, and 1.24 MAC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Desflurane (0.41, 0.83, and 1.24 MAC)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Desflurane (greater minimum alveolar concentration)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Sevoflurane (greater minimum alveolar concentration)
Number of subjects: 21
Study: 1387253

Group type: EXPERIMENTAL
Intervention: ondansetron
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study: 6338990

Group type: EXPERIMENTAL
Intervention: Metronidazole and ampicillin
Number of subjects: 283

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 283
Study: 31131501

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (Exparel) administered via transversus abdominis plane (TAP) block
Number of subjects: 46
Study: 30518055

Group type: EXPERIMENTAL
Intervention: 12-week nutrition education
Number of subjects: 71

Group type: COMPARATOR
Intervention: Printed educational materials
Number of subjects: 71
Study: 26238968

Group type: EXPERIMENTAL
Intervention: l-DOPA
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 23850615

Group type: EXPERIMENTAL
Intervention: Prolotherapy
Number of subjects: 37
Study: 21697609

Group type: EXPERIMENTAL
Intervention: LIPC group II (3 × 5‐min cycles of right upper arm ischemia and 5‐min reperfusion combined with 2 × 10‐min cycles of right upper leg ischemia and 10‐min reperfusion)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: LIPC group II
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 19549060

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16352669

Group type: EXPERIMENTAL
Intervention: Acyline (GnRH antagonist) for medical castration
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acyline plus daily testosterone gel
Number of subjects: 12
Study: 15303634

Group type: EXPERIMENTAL
Intervention: Gemifloxacin 320 mg once daily for 7 days
Number of subjects: 324

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate 1 g/125 mg three times daily for 10 days
Number of subjects: 324
Study: 11295696

Group type: EXPERIMENTAL
Intervention: Tc-99m-MIBI gated SPECT
Number of subjects: 56

Group type: COMPARATOR
Intervention: Tl-201 gated SPECT
Number of subjects: 56
Study: 8818261

Group type: EXPERIMENTAL
Intervention: Gut sutures
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid sutures
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Polyglactin 910 sutures
Number of subjects: 55
Study: 1441674

Group type: EXPERIMENTAL
Intervention: Hydrotalcite 1000 mg q.i.d.
Number of subjects: 159

Group type: COMPARATOR
Intervention: Ranitidine 300 mg at night
Number of subjects: 159
Study: 6737208

Group type: EXPERIMENTAL
Intervention: Aerobic exercise treatment
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo treatment (relaxation exercises)
Number of subjects: 43

Group type: COMPARATOR
Intervention: No-treatment condition
Number of subjects: 43
Study: 31756444

Group type: EXPERIMENTAL
Intervention: Higher genetically predicted levels of follicle stimulating hormones
Number of subjects: 2488

Group type: EXPERIMENTAL
Intervention: Higher predicted levels of luteinizing hormone
Number of subjects: 2488
Study: 29845672

Group type: EXPERIMENTAL
Intervention: Sodium pentosan polysulfate (Na‐PPS) 50 mg subcutaneously twice daily
Number of subjects: 109

Group type: COMPARATOR
Intervention: Standard thromboprophylaxis (enoxaparin 40 mg subcutaneously once daily or fondaparinux 2.5 mg once daily for Muslim women)
Number of subjects: 109
Study: 27328952

Group type: EXPERIMENTAL
Intervention: High dose atorvastatin (80 mg)
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Low dose atorvastatin (10 mg)
Number of subjects: 1171

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 1171
Study: 23436336

Group type: EXPERIMENTAL
Intervention: Budesonide MMX 9 mg
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Budesonide MMX 6 mg
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Entocort EC 9 mg
Number of subjects: 410

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 410
Study: 22835510

Group type: EXPERIMENTAL
Intervention: 10 mg/d lutein
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 20 mg/d lutein
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 10 mg/d lutein plus 10 mg/d zeaxanthin
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 20020090

Group type: EXPERIMENTAL
Intervention: Integration of non-university surgical departments into multicenter trials; no specific intervention details available.
Number of subjects: 0
Study: 17698432

Group type: EXPERIMENTAL
Intervention: Low-pressure CO2 insufflation (LPLC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Abdominal wall lifting (GLC)
Number of subjects: 80
Study: 15289993

Group type: EXPERIMENTAL
Intervention: Glucose 32.5 g/200 ml (G32.5)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose 75 g/200 ml (G75)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Aspartame 0.6 g/200 ml (A, placebo)
Number of subjects: 12
Study: 12170197

Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy (EBT) after PTA (192-Iridium)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No additional therapy after PTA
Number of subjects: 24
Study: 10443598

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 1 MAC Xe
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 0.7 MAC Xe
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Sevoflurane with 0.7 MAC N2O
Number of subjects: 43
Study: 7665880

Group type: EXPERIMENTAL
Intervention: Intraoperative contamination by Haemophilus species
Number of subjects: 193

Group type: COMPARATOR
Intervention: Negative cultures for Haemophilus species
Number of subjects: 193
Study: 2132289

Group type: EXPERIMENTAL
Intervention: Morniflumate (700 mg bid)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Tiaprofenic acid (300 mg bid)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paracetamol (10 ml syrup equivalent to 500 mg tid)
Number of subjects: 60
Study: 582394

Group type: EXPERIMENTAL
Intervention: 4 mg tinofedrine i.v.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 10
Study: 31358022

Group type: EXPERIMENTAL
Intervention: Capsulated Lactobacillus rhamnosus HN001 (6 × 10^9 colony-forming units/day)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cereal containing 4 g β-glucan
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 152

Group type: COMPARATOR
Intervention: Calorie-matched control cereal
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Capsulated Lactobacillus rhamnosus HN001 and cereal containing 4 g β-glucan
Number of subjects: 152
Study: 28767288

Group type: EXPERIMENTAL
Intervention: Arsenic trioxide (ATO) consolidation with reduced doses of anthracyclines
Number of subjects: 101

Group type: COMPARATOR
Intervention: Historical control (AIDA 0493) with higher anthracycline doses and no ATO consolidation
Number of subjects: 101
Study: 25030327

Group type: EXPERIMENTAL
Intervention: Contasure-Needleless (C-NDL®)
Number of subjects: 257

Group type: COMPARATOR
Intervention: Transobturator tension-free vaginal tape (TVT-O®)
Number of subjects: 257
Study: 23642147

Group type: EXPERIMENTAL
Intervention: Sterile water injections (0.1 to 0.3 millilitres)
Number of subjects: 1866

Group type: COMPARATOR
Intervention: Normal saline placebo
Number of subjects: 1866
Study: 21859657

Group type: EXPERIMENTAL
Intervention: 1.10 g/kg·d
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1.02 g/kg·d
Number of subjects: 20
Study: 19922897

Group type: EXPERIMENTAL
Intervention: Nebicapone 50 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nebicapone 100 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nebicapone 200 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 17084844

Group type: EXPERIMENTAL
Intervention: Oral E2/NETA 1 mg/0.5 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intranasal E2/NET 175 microg/275 microg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 90
Study: 14700647

Group type: EXPERIMENTAL
Intervention: Affected eyes (eyes that experienced optic neuritis)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Patients with multiple sclerosis (MS)
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Recurrent optic neuritis
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: National Eye Institute Visual Function Questionnaire
Number of subjects: 319
Study: 12575586

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) combined with Antike capsule (AC)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 89
Study: 9491025

Group type: EXPERIMENTAL
Intervention: Green prescription (written exercise advice)
Number of subjects: 456

Group type: COMPARATOR
Intervention: Verbal advice
Number of subjects: 456
Study: 7513171

Group type: COMPARATOR
Intervention: Biopsy prior to transplantation, shortly after opening of reanastomosis, at least once postoperatively (days 7‐10)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Follow-up biopsies from non-rejecting and rejecting patients
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Increased infiltration of T cells and macrophages
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Increased tubular and endothelial staining for MHC class II, ICAM‐1, and VCAM‐1
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Strong leukocytic expression of VLA‐4 and LFA‐1 alpha/beta
Number of subjects: 41
Study: 3369751

Group type: EXPERIMENTAL
Intervention: Albuterol aerosol, 200 micrograms via Aerochamber
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 30
Study: 30012812

Group type: EXPERIMENTAL
Intervention: D6 intervention (12 sessions over 12 months)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 334
Study: 27448179

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin DPI 32.5 mg
Number of subjects: 24
Study: 26122678

Group type: EXPERIMENTAL
Intervention: Stability balls as chairs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chairs as usual (control)
Number of subjects: 0
Study: 23443608

Group type: EXPERIMENTAL
Intervention: Single doses of 0.5 Gy
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Single doses of 1.0 Gy
Number of subjects: 457

Group type: COMPARATOR
Intervention: Both 0.5 Gy and 1.0 Gy groups
Number of subjects: 457
Study: 20719808

Group type: EXPERIMENTAL
Intervention: Computer-administered version of the Word Memory Test (WMT)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Orally administered version of the Word Memory Test (WMT)
Number of subjects: 125
Study: 18766404

Group type: EXPERIMENTAL
Intervention: Preoperative irradiation (5 x 5 Gy) with immediate total mesorectal excision (TME)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Chemoradiation (50.4 Gy, bolus 5-fluorouracil and leucovorin) with delayed TME
Number of subjects: 312
Study: 15671107

Group type: EXPERIMENTAL
Intervention: 4 mg 17beta‐estradiol (ET)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 4 mg 17beta‐estradiol combined with 10 mg dydrogesterone (EPT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 25
Study: 12906976

Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg for 6 weeks
Number of subjects: 150
Study: 10496712

Group type: EXPERIMENTAL
Intervention: r‐ProUK 2 mg/hr
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: r‐ProUK 4 mg/hr
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: r‐ProUK 8 mg/hr
Number of subjects: 241

Group type: COMPARATOR
Intervention: Urokinase (4,000 IU/min for 4 hrs, then 2,000 IU/min)
Number of subjects: 241
Study: 8604260

Group type: EXPERIMENTAL
Intervention: Adenosine infusion (25 to 50 microg/kg/min over 24 hours)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo infusion of normal saline
Number of subjects: 18
Study: 1682735

Group type: EXPERIMENTAL
Intervention: Reticulin antibodies
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Gliadin antibodies
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Follow-up of reticulin-antibody-positive relatives
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Genetic comparison of reticulin-antibody-positive relatives
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Genetic comparison of gliadin-antibody-positive relatives
Number of subjects: 122
Study: 7438470

Group type: EXPERIMENTAL
Intervention: metoclopramide
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: bromocriptine
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27
Study: 30918101

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 100 U
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 75 U
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 28646140

Group type: EXPERIMENTAL
Intervention: Low AGE diet
Number of subjects: 20
Study: 25433040

Group type: EXPERIMENTAL
Intervention: Ciclosporin (1-5 mg/kg/day) plus steroids
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: MTX (15-25 mg weekly) plus steroids
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Ciclosporin/MTX combination therapy plus steroids
Number of subjects: 58

Group type: COMPARATOR
Intervention: Steroids alone (placebo control)
Number of subjects: 58
Study: 23833855

Group type: EXPERIMENTAL
Intervention: Nerve block with bupivacaine 0.5% with epinephrine
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 21640931

Group type: EXPERIMENTAL
Intervention: MGuard-based PCI
Number of subjects: 41
Study: 19713649

Group type: EXPERIMENTAL
Intervention: Water exercise group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Land exercise group
Number of subjects: 0
Study: 16686567

Group type: EXPERIMENTAL
Intervention: Active group without expectancy instructions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo group with expectancy instructions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo group without expectancy instructions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Active group with expectancy instructions
Number of subjects: 48
Study: 15457380

Group type: EXPERIMENTAL
Intervention: Laparoscopic procedure
Number of subjects: 171

Group type: COMPARATOR
Intervention: Open technique
Number of subjects: 171
Study: 11253738

Group type: EXPERIMENTAL
Intervention: 20 mg nicorandil
Number of subjects: 11

Group type: COMPARATOR
Intervention: No premedication (control)
Number of subjects: 11
Study: 9280552

Group type: EXPERIMENTAL
Intervention: Estradiol gel TX 11323 (A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Transdermal matrix system delivering 50 micrograms/24 h of estradiol
Number of subjects: 80
Study: 7687978

Group type: COMPARATOR
Intervention: 10 MU/m2 interferon‐alpha‐2a, three times a week for 6 months (group 1, n = 20)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 90 mg/m2 of levamisole for 45 days, together with 10 MU/m2 of interferon‐alpha‐2a, three times a week for 6 months (group 2, n = 18)
Number of subjects: 38